All Title Author
Keywords Abstract

PLOS ONE  2012 

Androgen-Regulated Transcriptional Control of Sialyltransferases in Prostate Cancer Cells

DOI: 10.1371/journal.pone.0031234

Full-Text   Cite this paper   Add to My Lib

Abstract:

The expression of gangliosides is often associated with cancer progression. Sialyltransferases have received much attention in terms of their relationship with cancer because they modulate the expression of gangliosides. We previously demonstrated that GD1a production was high in castration-resistant prostate cancer cell lines, PC3 and DU145, mainly due to their high expression of β-galactoside α2,3-sialyltransferase (ST3Gal) II (not ST3Gal I), and the expression of both ST3Gals was regulated by NF-κB, mainly by RelB. We herein demonstrate that GD1a was produced in abundance in cancerous tissue samples from human patients with hormone-sensitive prostate cancers as well as castration-resistant prostate cancers. The expression of ST3Gal II was constitutively activated in castration-resistant prostate cancer cell lines, PC3 and DU145, because of the hypomethylation of CpG island in its promoter. However, in androgen-depleted LNCap cells, a hormone-sensitive prostate cancer cell line, the expression of ST3Gal II was silenced because of the hypermethylation of the promoter region. The expression of ST3Gal II in LNCap cells increased with testosterone treatment because of the demethylation of the CpG sites. This testosterone-dependent ST3Gal II expression was suppressed by RelB siRNA, indicating that RelB activated ST3Gal II transcription in the testosterone-induced demethylated promoter. Therefore, in hormone-sensitive prostate cancers, the production of GD1a may be regulated by androgen. This is the first report indicating that the expression of a sialyltransferase is transcriptionally regulated by androgen-dependent demethylation of the CpG sites in its gene promoter.

References

[1]  Dall'Olio F, Chiricolo M (2001) Sialyltransferases in cancer. Glycoconj J 18: 841–850.
[2]  Hakomori S (2002) Glycosylation defining cancer malignancy: new wine in an old bottle. Proc Natl Acad Sci U S A 99: 10231–10233.
[3]  Birklé S, Zeng G, Gao L, Yu RK, Aubry J (2003) Role of tumor-associated gangliosides in cancer progression. Biochimie 85: 455–463.
[4]  Yamashita T, Wada R, Sasaki T, Deng C, Bierfreund U, et al. (1999) A vital role for glycosphingolipid synthesis during development and differentiation. Proc Natl Acad Sci U S A 96: 9142–9147.
[5]  Varki NM, Varki A (2007) Diversity in cell surface sialic acid presentations: implications for biology and disease. Lab Invest 87: 851–857.
[6]  Takashima S (2008) Characterization of mouse sialyltransferase genes: their evolution and diversity. Biosci Biotechnol Biochem 72: 1155–1167.
[7]  Bos PD, Zhang XH, Nadal C, Shu W, Gomis RR, et al. (2009) Genes that mediate breast cancer metastasis to the brain. Nature 459: 1005–1009.
[8]  Houghton AN, Mintzer D, Cordon-Cardo C, Welt S, Fliegel B, et al. (1985) Mouse monoclonal IgG3 antibody detecting GD3 ganglioside: a phase I trial in patients with malignant melanoma. Proc Natl Acad Sci U S A 82: 1242–1246.
[9]  Zhang S, Cordon-Cardo C, Zhang HS, Reuter VE, Adluri S, et al. (1997) Selection of tumor antigens as targets for immune attack using immunohistochemistry: I. Focus on gangliosides. Int J Cancer 73: 42–49.
[10]  Yu AL, Gilman AL, Ozkaynak MF, London WB, Kreissman SG, et al. (2010) Children's Oncology Group. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med 363: 1324–1334.
[11]  Taki T, Ishikawa D, Ogura M, Nakajima M, Handa S (1997) Ganglioside GD1alpha functions in the adhesion of metastatic tumor cells to endothelial cells of the target tissue. Cancer Res 57: 1882–1888.
[12]  Li R, Liu Y, Ladisch S (2001) Enhancement of epidermal growth factor signaling and activation of SRC kinase by gangliosides. J Biol Chem 276: 42782–42792.
[13]  Lang Z, Guerrera M, Li R, Ladisch S (2001) Ganglioside GD1a enhances VEGF-induced endothelial cell proliferation and migration. Biochem Biophys Res Commun 282: 1031–1037.
[14]  Liu Y, Li R, Ladisch S (2004) Exogenous ganglioside GD1a enhances epidermal growth factor receptor binding and dimerization. J Biol Chem 279: 36481–36489.
[15]  Liu Y, McCarthy J, Ladisch S (2006) Membrane ganglioside enrichment lowers the threshold for vascular endothelial cell angiogenic signaling. Cancer Res 66: 10408–10414.
[16]  Villar E, Barroso IM (2006) Role of sialic acid-containing molecules in paramyxovirus entry into the host cell: a minireview. Glycoconj J 23: 5–17.
[17]  Kawaguchi Y, Miyamoto Y, Inoue T, Kaneda Y (2009) Efficient eradication of hormone-resistant human prostate cancers by inactivated Sendai virus particle. Int J Cancer 124: 2478–2487.
[18]  Ravindranath MH, Muthugounder S, Presser N, Selvan SR, Portoukalian J, et al. (2004) Gangliosides of organ-confined versus metastatic androgen-receptor-negative prostate cancer. Biochem Biophys Res Commun 324: 154–165.
[19]  Ravindranath MH, Muthugounder S, Presser N, Ye X, Brosman S, et al. (2005) Endogenous immune response to gangliosides in patients with confined prostate cancer. Int J Cancer 116: 368–377.
[20]  Hatano K, Miyamoto Y, Nonomura N, Kaneda Y (2011) Expression of gangliosides, GD1a and sialyl paragloboside, is regulated by NF-κB-dependent transcriptional control of α2,3-sialyltransferase I, II and VI in human castration-resistant prostate cancer cells. Int J Cancer 129: 1838–1847.
[21]  Lee YC, Kojima N, Wada E, Kurosawa N, Nakaoka T, et al. (1994) Cloning and expression of cDNA for a new type of Gal beta 1,3GalNAc alpha 2,3-sialyltransferase. J Biol Chem 269: 10028–10033.
[22]  Kojima N, Lee YC, Hamamoto T, Kurosawa N, Tsuji S (1994) Kinetic properties and acceptor substrate preferences of two kinds of Gal beta 1,3GalNAc alpha 2,3-sialyltransferase from mouse brain. Biochemistry 33: 5772–5776.
[23]  Tsuji S (1996) Molecular cloning and functional analysis of sialyltransferases. J Biochem 120: 1–13.
[24]  Kono M, Ohyama Y, Lee YC, Hamamoto T, Kojima N, et al. (1997) Mouse beta-galactoside alpha 2,3-sialyltransferases: comparison of in vitro substrate specificities and tissue specific expression. Glycobiology 7: 469–479.
[25]  Heinlein CA, Chang C (2004) Androgen receptor in prostate cancer. Endocr Rev 25: 276–308.
[26]  Herman JG, Graff JR, My?h?nen S, Nelkin BD, Baylin SB (1996) Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A 93: 9821–9826.
[27]  Nakayama M, Bennett CJ, Hicks JL, Epstein JI, Platz EA, et al. (2003) Hypermethylation of the human glutathione S-transferase-pi gene (GSTP1) CpG island is present in a subset of proliferative inflammatory atrophy lesions but not in normal or hyperplastic epithelium of the prostate: a detailed study using laser-capture microdissection. Am J Pathol 163: 923–933.
[28]  Korekane H, Tsuji S, Noura S, Ohue M, Sasaki Y, et al. (2007) Novel fucogangliosides found in human colon adenocarcinoma tissues by means of glycomic analysis. Anal Biochem 364: 37–50.
[29]  Sedelaar JP, Isaacs JT (2009) Tissue culture media supplemented with 10% fetal calf serum contains a castrate level of testosterone. Prostate 69: 1724–1729.
[30]  Taniguchi A, Morishima T, Tsujita Y, Matsumoto Y, Matsumoto K (2003) Genomic structure, expression, and transcriptional regulation of human Gal beta 1,3 GalNAc alpha 2,3-sialyltransferase gene. Biochem Biophys Res Commun 300: 570–576.
[31]  Taniguchi A, Yoshikawa I, Matsumoto K (2001) Genomic structure and transcriptional regulation of human Galbeta1,3GalNAc alpha2,3-sialyltransferase (hST3Gal I) gene. Glycobiology 11: 241–247.
[32]  Lessard L, Bégin LR, Gleave ME, Mes-Masson AM, Saad F (2005) Nuclear localisation of nuclear factor-kappaB transcription factors in prostate cancer: an immunohistochemical study. Br J Cancer 93: 1019–1023.
[33]  Keller ET, Chang C, Ershler WB (1996) Inhibition of NFkappaB activity through maintenance of IkappaBalpha levels contributes to dihydrotestosterone-mediated repression of the interleukin-6 promoter. J Biol Chem 271: 26267–26275.
[34]  Ripple MO, Henry WF, Schwarze SR, Wilding G, Weindruch R (1999) Effect of antioxidants on androgen-induced AP-1 and NF-kappaB DNA-binding activity in prostate carcinoma cells. J Natl Cancer Inst 91: 1227–1232.
[35]  Bollrath J, Greten FR (2009) IKK/NF-kappaB and STAT3 pathways: central signaling hubs in inflammation-mediated tumour promotion and metastasis. EMBO Rep 10: 1314–1319.
[36]  Lupien M, Eeckhoute J, Meyer CA, Wang Q, Zhang Y, et al. (2008) FoxA1 translates epigenetic signatures into enhancer-driven lineage-specific transcription. Cell 132: 958–970.
[37]  Wang Q, Li W, Zhang Y, Yuan X, Xu K, et al. (2009) Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell 138: 245–256.
[38]  Yegnasubramanian S, Haffner MC, Zhang Y, Gurel B, Cornish TC, et al. (2008) DNA hypomethylation arises later in prostate cancer progression than CpG island hypermethylation and contributes to metastatic tumor heterogeneity. Cancer Res 68: 8954–8967.
[39]  Nelson WG, De Marzo AM, Yegnasubramanian S (2009) Epigenetic alterations in human prostate cancers. Endocrinology 150: 3991–4002.
[40]  Métivier R, Gallais R, Tiffoche C, Le Péron C, Jurkowska RZ, et al. (2008) Cyclical DNA methylation of a transcriptionally active promoter. Nature 452: 45–50.
[41]  Kangaspeska S, Stride B, Métivier R, Polycarpou-Schwarz M, Ibberson D, et al. (2008) Transient cyclical methylation of promoter DNA. Nature 452: 112–115.
[42]  Wiench M, John S, Baek S, Johnson TA, Sung MH, et al. (2011) DNA methylation status predicts cell type-specific enhancer activity. EMBO J 30: 3028–3039.
[43]  Kim MS, Kondo T, Takada I, Youn MY, Yamamoto Y, et al. (2009) DNA demethylation in hormone-induced transcriptional derepression. Nature 461: 1007–1012.
[44]  Ng HH, Zhang Y, Hendrich B, Johnson CA, Turner BM, et al. (1999) MBD2 is a transcriptional repressor belonging to the MeCP1 histone deacetylase complex. Nat Genet 23: 58–61.
[45]  Sharma D, Blum J, Yang X, Beaulieu N, Macleod AR, et al. (2005) Release of methyl CpG binding proteins and histone deacetylase 1 from the Estrogen receptor alpha (ER) promoter upon reactivation in ER-negative human breast cancer cells. Mol Endocrinol 19: 1740–1751.
[46]  Freytag SO, Stricker H, Movsas B, Kim JH (2007) Prostate cancer gene therapy clinical trials. Mol Ther 15: 1042–1052.
[47]  Li X, Liu Y, Tang Y, Roger P, Jeng MH, et al. (2010) Docetaxel increases antitumor efficacy of oncolytic prostate-restricted replicative adenovirus by enhancing cell killing and virus distribution. J Gene Med 12: 516–527.
[48]  Castelo-Branco P, Passer BJ, Buhrman JS, Antoszczyk S, Marinelli M, et al. (2010) Oncolytic herpes simplex virus armed with xenogeneic homologue of prostatic acid phosphatase enhances antitumor efficacy in prostate cancer. Gene Ther 17: 805–810.

Full-Text

comments powered by Disqus